Search

Your search keyword '"Doi, Yohei"' showing total 1,577 results
Start Over Author "Doi, Yohei"
1,577 results on '"Doi, Yohei"'

5. Clinical Impact of Ceftriaxone Resistance in Escherichia coli Bloodstream Infections: A Multicenter Prospective Cohort Study

Author

Tamma, Pranita D, Komarow, Lauren, Ge, Lizhao, Garcia-Diaz, Julia, Herc, Erica S, Doi, Yohei, Arias, Cesar A, Albin, Owen, Saade, Elie, Miller, Loren G, Jacob, Jesse T, Satlin, Michael J, Krsak, Martin, Huskins, W Charles, Dhar, Sorabh, Shelburne, Samuel A, Hill, Carol, Baum, Keri R, Bhojani, Minal, Greenwood-Quaintance, Kerryl E, Schmidt-Malan, Suzannah M, Patel, Robin, Evans, Scott R, Chambers, Henry F, Fowler, Vance G, van Duin, David, and Group, for the Antibacterial Resistance Leadership

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Hematology, Sepsis, Infection, bacteremia, ceftriaxone, Escherichia coli, ESBL, mortality, resistance, Antibacterial Resistance Leadership Group, Clinical sciences, Medical microbiology
Abstract

BackgroundCeftriaxone-resistant (CRO-R) Escherichia coli bloodstream infections (BSIs) are common.MethodsThis is a prospective cohort of patients with E coli BSI at 14 United States hospitals between November 2020 and April 2021. For each patient with a CRO-R E coli BSI enrolled, the next consecutive patient with a ceftriaxone-susceptible (CRO-S) E coli BSI was included. Primary outcome was desirability of outcome ranking (DOOR) at day 30, with 50% probability of worse outcomes in the CRO-R group as the null hypothesis. Inverse probability weighting (IPW) was used to reduce confounding.ResultsNotable differences between patients infected with CRO-R and CRO-S E coli BSI included the proportion with Pitt bacteremia score ≥4 (23% vs 15%, P = .079) and the median time to active antibiotic therapy (12 hours [interquartile range {IQR}, 1-35 hours] vs 1 hour [IQR, 0-6 hours]; P < .001). Unadjusted DOOR analyses indicated a 58% probability (95% confidence interval [CI], 52%-63%) for a worse clinical outcome in CRO-R versus CRO-S BSI. In the IPW-adjusted cohort, no difference was observed (54% [95% CI, 47%-61%]). Secondary outcomes included unadjusted and adjusted differences in the proportion of 30-day mortality between CRO-R and CRO-S BSIs (-5.3% [95% CI, -10.3% to -.4%] and -1.8 [95% CI, -6.7% to 3.2%], respectively), postculture median length of stay (8 days [IQR, 5-13 days] vs 6 days [IQR, 4-9 days]; P < .001), and incident admission to a long-term care facility (22% vs 12%, P = .045).ConclusionsPatients with CRO-R E coli BSI generally have poorer outcomes compared to patients infected with CRO-S E coli BSI, even after adjusting for important confounders.

Published
2022

10. Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study

Author

Wang, Minggui, Earley, Michelle, Chen, Liang, Hanson, Blake M, Yu, Yunsong, Liu, Zhengyin, Salcedo, Soraya, Cober, Eric, Li, Lanjuan, Kanj, Souha S, Gao, Hainv, Munita, Jose M, Ordoñez, Karen, Weston, Greg, Satlin, Michael J, Valderrama-Beltrán, Sandra L, Marimuthu, Kalisvar, Stryjewski, Martin E, Komarow, Lauren, Luterbach, Courtney, Marshall, Steve H, Rudin, Susan D, Manca, Claudia, Paterson, David L, Reyes, Jinnethe, Villegas, Maria V, Evans, Scott, Hill, Carol, Arias, Rebekka, Baum, Keri, Fries, Bettina C, Doi, Yohei, Patel, Robin, Kreiswirth, Barry N, Bonomo, Robert A, Chambers, Henry F, Fowler, Vance G, Arias, Cesar A, van Duin, David, Investigators, Multi-Drug Resistant Organism Network, Abbo, Lilian M, Anderson, Deverick J, Chew, Kean Lee, Cross, Heather R, De, Partha Pratim, Desai, Samit, Dhar, Sorabh, Di Castelnuovo, Valentina, Diaz, Lorena, Dinh, AN Q, Eilertson, Brandon, Evans, Beth, Garcia-Diaz, Julia, Garner, Omai B, Greenwood-Quaintance, Kerryl, Hanson, Blake, Herc, Erica, Jacob, Jesse T, Jiang, Jianping, Kalayjian, Robert C, Kaye, Keith S, Kim, Angela, Lauterbach, Courtney, Marshall, Steven H, McCarty, Todd, Munita, Jose, Ng, Oon Tek, Gutierrez, Jose Millan Oñate, Peleg, Anton, Salata, Robert A, Schmidt-Malan, Suzannah, and Smitasin, Nares

Subjects
Pneumonia & Influenza, Lung, Clinical Research, Pneumonia, Infectious Diseases, Infection, Good Health and Well Being, Anti-Bacterial Agents, Bacteremia, Carbapenem-Resistant Enterobacteriaceae, Carbapenems, Cohort Studies, Humans, Klebsiella Infections, Klebsiella pneumoniae, Prospective Studies, Respiratory Sounds, Multi-Drug Resistant Organism Network Investigators, Clinical Sciences, Medical Microbiology, Public Health and Health Services, Microbiology
Abstract

BackgroundCarbapenem-resistant Klebsiella pneumoniae (CRKP) is a global threat. We therefore analysed the bacterial characteristics of CRKP infections and the clinical outcomes of patients with CRKP infections across different countries.MethodsIn this prospective, multicentre, cohort study (CRACKLE-2), hospitalised patients with cultures positive for CRKP were recruited from 71 hospitals in Argentina, Australia, Chile, China, Colombia, Lebanon, Singapore, and the USA. The first culture positive for CRKP was included for each unique patient. Clinical data on post-hospitalisation death and readmission were collected from health records, and whole genome sequencing was done on all isolates. The primary outcome was a desirability of outcome ranking at 30 days after the index culture, and, along with bacterial characteristics and 30-day all-cause mortality (a key secondary outcome), was compared between patients from China, South America, and the USA. The desirability of outcome ranking was adjusted for location before admission, Charlson comorbidity index, age at culture, Pitt bacteremia score, and anatomical culture source through inverse probability weighting; mortality was adjusted for the same confounders, plus region where relevant, through multivariable logistic regression. This study is registered at ClinicalTrials.gov, NCT03646227, and is complete.FindingsBetween June 13, 2017, and Nov 30, 2018, 991 patients were enrolled, of whom 502 (51%) met the criteria for CRKP infection and 489 (49%) had positive cultures that were considered colonisation. We observed little intra-country genetic variation in CRKP. Infected patients from the USA were more acutely ill than were patients from China or South America (median Pitt bacteremia score 3 [IQR 2-6] vs 2 [0-4] vs 2 [0-4]) and had more comorbidities (median Charlson comorbidity index 3 [IQR 2-5] vs 1 [0-3] vs 1 [0-2]). Adjusted desirability of outcome ranking outcomes were similar in infected patients from China (n=246), South America (n=109), and the USA (n=130); the estimates were 53% (95% CI 42-65) for China versus South America, 50% (41-61) for the USA versus China, and 53% (41-66) for the USA versus South America. In patients with CRKP infections, unadjusted 30-day mortality was lower in China (12%, 95% CI 8-16; 29 of 246) than in the USA (23%, 16-30; 30 of 130) and South America (28%, 20-37; 31 of 109). Adjusted 30-day all-cause mortality was higher in South America than in China (adjusted odds ratio [aOR] 4·82, 95% CI 2·22-10·50) and the USA (aOR 3·34, 1·50-7·47), with the mortality difference between the USA and China no longer being significant (aOR 1·44, 0·70-2·96).InterpretationGlobal CRKP epidemics have important regional differences in patients' baseline characteristics and clinical outcomes, and in bacterial characteristics. Research findings from one region might not be generalisable to other regions.FundingThe National Institutes of Health.

Published
2022

13. Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study

Author

van Duin, David, Arias, Cesar A, Komarow, Lauren, Chen, Liang, Hanson, Blake M, Weston, Gregory, Cober, Eric, Garner, Omai B, Jacob, Jesse T, Satlin, Michael J, Fries, Bettina C, Garcia-Diaz, Julia, Doi, Yohei, Dhar, Sorabh, Kaye, Keith S, Earley, Michelle, Hujer, Andrea M, Hujer, Kristine M, Domitrovic, T Nicholas, Shropshire, William C, Dinh, An, Manca, Claudia, Luterbach, Courtney L, Wang, Minggui, Paterson, David L, Banerjee, Ritu, Patel, Robin, Evans, Scott, Hill, Carol, Arias, Rebekka, Chambers, Henry F, Fowler, Vance G, Kreiswirth, Barry N, Bonomo, Robert A, and Investigators, Multi-Drug Resistant Organism Network

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Prevention, Infectious Diseases, Clinical Research, Lung, Infection, Good Health and Well Being, Aged, Carbapenem-Resistant Enterobacteriaceae, Cohort Studies, Enterobacteriaceae Infections, Female, Humans, Male, Middle Aged, Phylogeny, Prospective Studies, United States, Multi-Drug Resistant Organism Network Investigators, Public Health and Health Services, Microbiology, Clinical sciences, Medical microbiology, Epidemiology
Abstract

BackgroundCarbapenem-resistant Enterobacterales (CRE) are a global threat. We aimed to describe the clinical and molecular characteristics of Centers for Disease Control and Prevention (CDC)-defined CRE in the USA.MethodsCRACKLE-2 is a prospective, multicentre, cohort study. Patients hospitalised in 49 US hospitals, with clinical cultures positive for CDC-defined CRE between April 30, 2016, and Aug 31, 2017, were included. There was no age exclusion. The primary outcome was desirability of outcome ranking (DOOR) at 30 days after index culture. Clinical data and bacteria were collected, and whole genome sequencing was done. This trial is registered with ClinicalTrials.gov, number NCT03646227.Findings1040 patients with unique isolates were included, 449 (43%) with infection and 591 (57%) with colonisation. The CDC-defined CRE admission rate was 57 per 100 000 admissions (95% CI 45-71). Three subsets of CDC-defined CRE were identified: carbapenemase-producing Enterobacterales (618 [59%] of 1040), non-carbapenemase-producing Enterobacterales (194 [19%]), and unconfirmed CRE (228 [22%]; initially reported as CRE, but susceptible to carbapenems in two central laboratories). Klebsiella pneumoniae carbapenemase-producing clonal group 258 K pneumoniae was the most common carbapenemase-producing Enterobacterales. In 449 patients with CDC-defined CRE infections, DOOR outcomes were not significantly different in patients with carbapenemase-producing Enterobacterales, non-carbapenemase-producing Enterobacterales, and unconfirmed CRE. At 30 days 107 (24%, 95% CI 20-28) of these patients had died.InterpretationAmong patients with CDC-defined CRE, similar outcomes were observed among three subgroups, including the novel unconfirmed CRE group. CDC-defined CRE represent diverse bacteria, whose spread might not respond to interventions directed to carbapenemase-producing Enterobacterales.FundingNational Institutes of Health.

Published
2020

16. Newly developed artificial intelligence algorithm for COVID-19 pneumonia: utility of quantitative CT texture analysis for prediction of favipiravir treatment effect

Author

Ohno, Yoshiharu, Aoyagi, Kota, Arakita, Kazumasa, Doi, Yohei, Kondo, Masashi, Banno, Sumi, Kasahara, Kei, Ogawa, Taku, Kato, Hideaki, Hase, Ryota, Kashizaki, Fumihiro, Nishi, Koichi, Kamio, Tadashi, Mitamura, Keiko, Ikeda, Nobuhiro, Nakagawa, Atsushi, Fujisawa, Yasuko, Taniguchi, Akira, Ikeda, Hirotaka, Hattori, Hidekazu, Murayama, Kazuhiro, and Toyama, Hiroshi

Published
2022
Full Text
View/download PDF

17. Clinical outcomes in patients infected with ertapenem-only-resistant Enterobacterales versus multi-carbapenem-resistant Enterobacterales

Author

Weston, Gregory, primary, Giri, Abhigya, additional, Komarow, Lauren, additional, Ge, Lizhao, additional, Baum, Keri R, additional, Abbenante, Erin, additional, Gallagher, Jason C, additional, Jacob, Jesse T, additional, Kaye, Keith S, additional, Kim, Angela C, additional, Huskins, W Charles, additional, Zervos, Marcus, additional, Herc, Erica, additional, Patel, Robin, additional, Van Duin, David, additional, and Doi, Yohei, additional

Published
2024
Full Text
View/download PDF

18. Clinical characteristics and genome epidemiology of Stenotrophomonas maltophilia in Japan

Author

Hase, Ryota, primary, Sakurai, Aki, additional, Suzuki, Masahiro, additional, Itoh, Naoya, additional, Hayakawa, Kayoko, additional, Uemura, Kohei, additional, Matsumura, Yasufumi, additional, Kato, Hideaki, additional, Ishihara, Takuma, additional, van Duin, David, additional, Ohmagari, Norio, additional, Doi, Yohei, additional, and Saito, Sho, additional

Published
2024
Full Text
View/download PDF

19. #410 Novel renal pathology and treatment of TIN with monoclonal plasma cells invasion in a patient with Sjögren's syndrome and IgA monoclonal gammopathy

Author

Hesaka, Atsushi, primary, Hirata, Yutaro, additional, Kubota, Takuya, additional, Sakai, Shinsuke, additional, Doi, Yohei, additional, Namba-Hamano, Tomoko, additional, Takahashi, Atsushi, additional, Mizui, Masayuki, additional, Kaimori, Jun-Ya, additional, and Isaka, Yoshitaka, additional

Published
2024
Full Text
View/download PDF

20. Pseudomonas aeruginosa Lipid A Structural Variants Induce Altered Immune Responses

Author

Hofstaedter, Casey E., primary, O'Keefe, Ian P., additional, Met, Charles M, additional, Wu, Ling, additional, Vanderwoude, Jelly, additional, Shin, Sunny, additional, Diggle, Stephen P, additional, Riquelme, Sebastian A, additional, Rasko, David A, additional, Doi, Yohei, additional, Harro, Janette M, additional, Kopp, Benjamin T., additional, and Ernst, Robert K, additional

Published
2024
Full Text
View/download PDF

21. Effectiveness of Favipiravir on Nonsevere, Early-Stage COVID-19 in Japan: A Large Observational Study Using the COVID-19 Registry Japan

Author

Tsuzuki, Shinya, Hayakawa, Kayoko, Doi, Yohei, Shinozaki, Tomohiro, Uemura, Yukari, Matsunaga, Nobuaki, Terada, Mari, Suzuki, Setsuko, Asai, Yusuke, Yamada, Gen, Saito, Sho, Shibata, Taro, Kondo, Masashi, Izumi, Kazuo, Hojo, Masayuki, Mizoue, Tetsuya, Yokota, Kazuhisa, Nakamura-Uchiyama, Fukumi, Saito, Fumitake, Sugiura, Wataru, and Ohmagari, Norio

Published
2022
Full Text
View/download PDF

24. Pseudomonas aeruginosa utilizes host polyunsaturated phosphatidylethanolamines to trigger theft-ferroptosis in bronchial epithelium.

Author

Dar, Haider, Tyurina, Yulia, Mikulska-Ruminska, Karolina, Shrivastava, Indira, Ting, Hsiu-Chi, Tyurin, Vladimir, Krieger, James, St Croix, Claudette, Watkins, Simon, Bayir, Erkan, Mao, Gaowei, Armbruster, Catherine, Kapralov, Alexandr, Wang, Hong, Parsek, Matthew, Anthonymuthu, Tamil, Ogunsola, Abiola, Flitter, Becca, Freedman, Cody, Gaston, Jordan, Holman, Theodore, Pilewski, Joseph, Greenberger, Joel, Mallampalli, Rama, Doi, Yohei, Lee, Janet, Bahar, Ivet, Bomberger, Jennifer, Bayır, Hülya, and Kagan, Valerian

Subjects
Bacterial infections, Cell Biology, Infectious disease, Apoptosis, Cell Line, Cystic Fibrosis, Epithelial Cells, Humans, Phosphatidylethanolamines, Pseudomonas Infections, Pseudomonas aeruginosa, Respiratory Mucosa, Respiratory Tract Infections
Abstract

Ferroptosis is a death program executed via selective oxidation of arachidonic acid-phosphatidylethanolamines (AA-PE) by 15-lipoxygenases. In mammalian cells and tissues, ferroptosis has been pathogenically associated with brain, kidney, and liver injury/diseases. We discovered that a prokaryotic bacterium, Pseudomonas aeruginosa, that does not contain AA-PE can express lipoxygenase (pLoxA), oxidize host AA-PE to 15-hydroperoxy-AA-PE (15-HOO-AA-PE), and trigger ferroptosis in human bronchial epithelial cells. Induction of ferroptosis by clinical P. aeruginosa isolates from patients with persistent lower respiratory tract infections was dependent on the level and enzymatic activity of pLoxA. Redox phospholipidomics revealed elevated levels of oxidized AA-PE in airway tissues from patients with cystic fibrosis (CF) but not with emphysema or CF without P. aeruginosa. We believe that the evolutionarily conserved mechanism of pLoxA-driven ferroptosis may represent a potential therapeutic target against P. aeruginosa-associated diseases such as CF and persistent lower respiratory tract infections.

Published
2018

29. Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study

Author

Abbo, Lilian M, Anderson, Deverick J, Arias, Rebekka, Arias, Cesar A, Baum, Keri, Bonomo, Robert A, Chambers, Henry F, Chen, Liang, Chew, Kean Lee, Cober, Eric, Cross, Heather R, De, Partha Pratim, Desai, Samit, Dhar, Sorabh, Di Castelnuovo, Valentina, Diaz, Lorena, Dinh, AN Q, Doi, Yohei, Earley, Michelle, Eilertson, Brandon, Evans, Beth, Evans, Scott, Fowler Jr, Vance G, Fries, Bettina C, Gao, Hainv, Garcia-Diaz, Julia, Garner, Omai B, Greenwood-Quaintance, Kerryl, Hanson, Blake, Herc, Erica, Hill, Carol, Jacob, Jesse T, Jiang, Jianping, Kalayjian, Robert C, Kanj, Souha S, Kaye, Keith S, Kim, Angela, Komarow, Lauren, Kreiswirth, Barry N, Lauterbach, Courtney, Li, Lanjuan, Liu, Zhengyin, Manca, Claudia, Marimuthu, Kalisvar, Marshall, Steven H, McCarty, Todd, Munita, Jose, Ng, Oon Tek, Oñate Gutierrez, Jose Millan, Ordoñez, Karen, Patel, Robin, Paterson, David L, Peleg, Anton, Reyes, Jinnethe, Rudin, Susan D, Salata, Robert A, Salcedo, Soraya, Satlin, Michael J, Schmidt-Malan, Suzannah, Smitasin, Nares, Spencer, Maria, Stryjewski, Martin, Su, Jiachun, Tambyah, Paul Ananth, Valderrama, Sandra, van Duin, David, Villegas Botero, Maria Virginia, Wang, Minggui, Waters, Mary, Weston, Greg, Wong, Darren, Wortmann, Glenn, Yang, Yang, Yu, Yunsong, Zhang, Fujie, Hanson, Blake M, Munita, Jose M, Valderrama-Beltrán, Sandra L, Stryjewski, Martin E, Luterbach, Courtney, Marshall, Steve H, Villegas, Maria V, and Fowler, Vance G, Jr

Published
2022
Full Text
View/download PDF

33. Phase II Clinical Trial of Combination Therapy with Favipiravir and Methylprednisolone for COVID-19 with Non-Critical Respiratory Failure

Author

Shindo, Yuichiro, Kondoh, Yasuhiro, Kada, Akiko, Doi, Yohei, Tomii, Keisuke, Mukae, Hiroshi, Murata, Naohiko, Imai, Ryosuke, Okamoto, Masaki, Yamano, Yasuhiko, Miyazaki, Yasunari, Shinoda, Masahiro, Aso, Hiromichi, Izumi, Shinyu, Ishii, Haruyuki, Ito, Ryota, Saito, Akiko M., Saito, Toshiki I., and Hasegawa, Yoshinori

Published
2021
Full Text
View/download PDF

34. Procalcitonin-Guided Use of Antibiotics for Lower Respiratory Tract Infection

Author

Huang, David T, Yealy, Donald M, Filbin, Michael R, Brown, Aaron M, Chang, Chung-Chou H, Doi, Yohei, Donnino, Michael W, Fine, Jonathan, Fine, Michael J, Fischer, Michelle A, Holst, John M, Hou, Peter C, Kellum, John A, Khan, Feras, Kurz, Michael C, Lotfipour, Shahram, LoVecchio, Frank, Peck-Palmer, Octavia M, Pike, Francis, Prunty, Heather, Sherwin, Robert L, Southerland, Lauren, Terndrup, Thomas, Weissfeld, Lisa A, Yabes, Jonathan, and Angus, Derek C

Subjects
Clinical Research, Health Services, Infectious Diseases, Lung, Infection, Adult, Aged, Anti-Bacterial Agents, Bacterial Infections, Biomarkers, Calcitonin, Emergency Service, Hospital, Female, Guideline Adherence, Hospitalists, Humans, Inappropriate Prescribing, Male, Middle Aged, Pneumonia, Practice Guidelines as Topic, Practice Patterns, Physicians', Respiratory Tract Infections, ProACT Investigators, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundThe effect of procalcitonin-guided use of antibiotics on treatment for suspected lower respiratory tract infection is unclear.MethodsIn 14 U.S. hospitals with high adherence to quality measures for the treatment of pneumonia, we provided guidance for clinicians about national clinical practice recommendations for the treatment of lower respiratory tract infections and the interpretation of procalcitonin assays. We then randomly assigned patients who presented to the emergency department with a suspected lower respiratory tract infection and for whom the treating physician was uncertain whether antibiotic therapy was indicated to one of two groups: the procalcitonin group, in which the treating clinicians were provided with real-time initial (and serial, if the patient was hospitalized) procalcitonin assay results and an antibiotic use guideline with graded recommendations based on four tiers of procalcitonin levels, or the usual-care group. We hypothesized that within 30 days after enrollment the total antibiotic-days would be lower - and the percentage of patients with adverse outcomes would not be more than 4.5 percentage points higher - in the procalcitonin group than in the usual-care group.ResultsA total of 1656 patients were included in the final analysis cohort (826 randomly assigned to the procalcitonin group and 830 to the usual-care group), of whom 782 (47.2%) were hospitalized and 984 (59.4%) received antibiotics within 30 days. The treating clinician received procalcitonin assay results for 792 of 826 patients (95.9%) in the procalcitonin group (median time from sample collection to assay result, 77 minutes) and for 18 of 830 patients (2.2%) in the usual-care group. In both groups, the procalcitonin-level tier was associated with the decision to prescribe antibiotics in the emergency department. There was no significant difference between the procalcitonin group and the usual-care group in antibiotic-days (mean, 4.2 and 4.3 days, respectively; difference, -0.05 day; 95% confidence interval [CI], -0.6 to 0.5; P=0.87) or the proportion of patients with adverse outcomes (11.7% [96 patients] and 13.1% [109 patients]; difference, -1.5 percentage points; 95% CI, -4.6 to 1.7; P

Published
2018

35. Design and rationale of the Procalcitonin Antibiotic Consensus Trial (ProACT), a multicenter randomized trial of procalcitonin antibiotic guidance in lower respiratory tract infection

Author

Huang, David T, Angus, Derek C, Chang, Chung-Chou H, Doi, Yohei, Fine, Michael J, Kellum, John A, Peck-Palmer, Octavia M, Pike, Francis, Weissfeld, Lisa A, Yabes, Jonathan, Yealy, Donald M, and on behalf of the ProACT Investigators

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Lung, Clinical Research, Infectious Diseases, Clinical Trials and Supportive Activities, Infection, Anti-Bacterial Agents, Biomarkers, Calcitonin, Calcitonin Gene-Related Peptide, Decision Making, Emergency Service, Hospital, Female, Humans, Male, Outcome and Process Assessment, Health Care, Practice Guidelines as Topic, Protein Precursors, Research Design, Respiratory Tract Infections, Treatment Outcome, United States, ProACT Investigators, Anti-bacterial agents, Clinical trial, Methods, Procalcitonin, Respiratory tract infections, Clinical Sciences, Emergency & Critical Care Medicine, Clinical sciences, Health services and systems
Abstract

BackgroundOveruse of antibiotics is a major public health problem, contributing to growing antibiotic resistance. Procalcitonin has been reported to be commonly elevated in bacterial, but not viral infection. Multiple European trials found procalcitonin-guided care reduced antibiotic use in lower respiratory tract infection, with no apparent harm. However, applicability to US practice is limited due to trial design features impractical in the US, between-country differences, and residual safety concerns.MethodsThe Procalcitonin Antibiotic Consensus Trial (ProACT) is a multicenter randomized trial to determine the impact of a procalcitonin antibiotic prescribing guideline, implemented with basic reproducible strategies, in US patients with lower respiratory tract infection.DiscussionWe describe the trial methods using the Consolidated Standards of Reporting Trials (CONSORT) framework, and the rationale for key design decisions, including choice of eligibility criteria, choice of control arm, and approach to guideline implementation.Trial registrationClinicalTrials.gov NCT02130986 . Registered May 1, 2014.

Published
2017

37. Structural insights into the molecular mechanism of high-level ceftazidime–avibactam resistance conferred by CMY-185

Author

Kawai, Akito, primary, Shropshire, William C., additional, Suzuki, Masahiro, additional, Borjan, Jovan, additional, Aitken, Samuel L., additional, Bachman, William C., additional, McElheny, Christi L., additional, Bhatti, Micah M., additional, Shields, Ryan K., additional, Shelburne, Samuel A., additional, and Doi, Yohei, additional

Published
2024
Full Text
View/download PDF

39. In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals

Author

Iovleva, Alina, primary, McElheny, Christi L., additional, Fowler, Erin L., additional, Cober, Eric, additional, Herc, Erica S., additional, Arias, Cesar A., additional, Hill, Carol, additional, Baum, Keri, additional, Fowler, Jr., Vance G., additional, Chambers, Henry F., additional, Greenwood-Quaintance, Kerryl E., additional, Patel, Robin, additional, van Duin, David, additional, Bonomo, Robert A., additional, and Doi, Yohei, additional

Published
2024
Full Text
View/download PDF

40. In Vivo Evolution of a Klebsiella pneumoniae Capsule Defect With wcaJ Mutation Promotes Complement-Mediated Opsonophagocytosis During Recurrent Infection

Author

Bain, William, primary, Ahn, Brian, additional, Peñaloza, Hernán F, additional, McElheny, Christi L, additional, Tolman, Nathanial, additional, van der Geest, Rick, additional, Gonzalez-Ferrer, Shekina, additional, Chen, Nathalie, additional, An, Xiaojing, additional, Hosuru, Ria, additional, Tabary, Mohammadreza, additional, Papke, Erin, additional, Kohli, Naina, additional, Farooq, Nauman, additional, Bachman, William, additional, Olonisakin, Tolani F, additional, Xiong, Zeyu, additional, Griffith, Marissa P, additional, Sullivan, Mara, additional, Franks, Jonathan, additional, Mustapha, Mustapha M, additional, Iovleva, Alina, additional, Suber, Tomeka, additional, Shanks, Robert Q, additional, Ferreira, Viviana P, additional, Stolz, Donna B, additional, Van Tyne, Daria, additional, Doi, Yohei, additional, and Lee, Janet S, additional

Published
2024
Full Text
View/download PDF

45. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

Author

Bassetti, Matteo, Echols, Roger, Matsunaga, Yuko, Ariyasu, Mari, Doi, Yohei, Ferrer, Ricard, Lodise, Thomas P, Naas, Thierry, Niki, Yoshihito, Paterson, David L, Portsmouth, Simon, Torre-Cisneros, Julian, Toyoizumi, Kiichiro, Wunderink, Richard G, and Nagata, Tsutae D

Published
2021
Full Text
View/download PDF

48. Response to RMED-D-22–00,258.R1

Author

Ohno, Yoshiharu, Aoyagi, Kota, Arakita, Kazumasa, Doi, Yohei, Kondo, Masashi, Banno, Sumi, Kasahara, Kei, Ogawa, Taku, Kato, Hideaki, Hase, Ryota, Kashizaki, Fumihiro, Nishi, Koichi, Kamio, Tadashi, Mitamura, Keiko, Ikeda, Nobuhiro, Nakagawa, Atsushi, Fujisawa, Yasuko, Taniguchi, Akira, Ikeda, Hidetake, Hattori, Hidekazu, Murayama, Kazuhiro, and Toyama, Hiroshi

Published
2022
Full Text
View/download PDF

49. Lung Pathology of Mutually Exclusive Co-infection with SARS-CoV-2 and Streptococcus pneumoniae

Author

Tsukamoto, Tetsuya, Nakajima, Noriko, Sakurai, Aki, Nakajima, Masayuki, Sakurai, Eiko, Sato, Yuko, Takahashi, Kenta, Kanno, Takayuki, Kataoka, Michiko, Katano, Harutaka, Iwata, Mitsunaga, Doi, Yohei, and Suzuki, Tadaki

Subjects
Bacterial pneumonia -- Case studies -- Development and progression, Comorbidity -- Case studies -- Development and progression, Pneumonia -- Case studies -- Development and progression, Health
Abstract

Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1), has claimed >1 million lives worldwide (2). Respiratory failure is the leading cause of death from COVID-19; [...]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results